Peer-reviewedCC BY-NC-NDJPGN reports
Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series
- 1Children's Hospital of Philadelphia
Related
- Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) : A systematic review and meta-analysis
- Efficacy of plant extracts for metabolic dysfunction-associated steatotic liver disease: a network meta-analysis
- Functional and Metabolic Correlates of Age- and Sex-Normalized Handgrip Strength in Children with Metabolic Dysfunction-Associated Steatotic Liver Disease
- Hepatocyte senescence in metabolic dysfunction–associated steatotic liver disease (MASLD)
- The CYB5R3–mARC1 Redox Axis in Metabolic Dysfunction-associated Steatotic Liver Disease: Mechanistic Basis and Therapeutic Prospects across the Steatosis–Cirrhosis–Hepatocellular Carcinoma Spectrum
BibTeX
@article{perumpail2026tirzepatide,
title = {{Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series}},
author = {Brandon J. Perumpail and Andrea Tou and Jennifer Panganiban},
journal = {JPGN reports},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13656291},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Tirzepatide use in adolescents with metabolic dysfunction‐associated steatotic liver disease (MASLD): A case series
AU - Brandon J. Perumpail
AU - Andrea Tou
AU - Jennifer Panganiban
PY - 2026
DA - 2026/10/12
JO - JPGN reports
UR - https://europepmc.org/article/PMC/PMC13656291
SN - 2691-171X
ER -